Three new Cochrane reviews find evidence that GLP-1 drugs lead to clinically meaningful weight loss, though industry-funded ...

For standard GLP-1 usage, Roslin said that patients are started with a low dose and titrated up to clinical effect. That ...

GLP-1RAs improved RA disease activity, pain scores, weight, cholesterol, and HbA1c levels in patients with a BMI ≥27. Nearly one-third of patients discontinued GLP-1RA therapy due to gastrointestinal ...

President Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their ...

Anti-obesity drugs such as semaglutide (Ozempic, Wegovy) are also promising for the treatment of alcohol use disorder and alcohol-associated liver disease, as growing evidence suggests they reduce the ...

Please provide your email address to receive an email when new articles are posted on . GLP-1 receptor agonists have shown encouraging results in osteoarthritis. More studies are needed to clearly ...

Patients with plateaued weight loss or who reached their weight-related goals on a GLP-1 receptor agonist were able to ...

Patients with obesity and asthma who used GLP-1 receptor agonists had significantly fewer exacerbations and prednisone use ...

Because GLP-1 agonists seem to reduce patients’ desire for food, it isn’t surprising that they might also shrink or even extinguish other cravings.

A small study helps explain why some people taking Wegovy and similar weight-loss drugs cut back on alcohol, offering insight into potential new addiction therapies ...

"Type 2 diabetes in children and teens is increasing at an alarming rate, yet treatment options are limited, and this patient population remains underserved," said Kenneth Custer, Ph.D., executive ...